12 June - 13 June 2019

Targeting the Ubiquitin - Proteasome Pathway II

Organised by:

SCI's Fine Chemicals Group

London, UK

Join this event

Prices start from £150.00

Early bird offer ends 3 May 2019


Protein turnover is crucial in maintaining cellular homeostasis and this process is largely controlled by the Ubiquitin Proteasome Pathway (UPP). The pathway consists of an enzymatic cascade that links the polypeptide cofactor Ubiquitin to specific protein targets, which mark them for degradation by the proteasome. This cascade is highly regulated and impacts virtually all cellular processes including cell cycle progression, cell proliferation, cell differentiation and apoptosis. Malfunction of the UPP has been implicated in the development of diseases such as cancer, immune disorders and neurodegeneration.

The ability to understand and manipulate the UPP is a major objective in being able to manage disease biology. While the validity of this approach was first exemplified by the proteasome inhibitor bortezomib, approved by the FDA in 2003 and used in the treatment of multiple myeloma and mantle cell lymphoma, subsequent advances in understanding the role of different components in the UPP have allowed the development of other high quality chemical probes and inhibitors.


This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly expanding field.

It is targeted at academic and industrial scientists engaged in all aspects of research into the ubiquitin proteasome pathway and those interested in broadening their knowledge in this rapidly expanding field.


The full programme will be announced in due course.

Confirmed Speakers
  • Keynote: Prof Alessio Ciulli, University of Dundee
  • Jason Brown, Ubiquigent
  • Dr Tauseef Butt, Progenra Inc
  • Dr Davide Gianni, AstraZeneca, Cambridge
  • Marcus Hartmann, Max Planck Institute for Developmental Biology
  • Dr David House, Crick-GSK Biomedical LinkLabs
  • Christiane Kofink, Boehringer Ingelheim
  • Kristin Riching, Promega

Venue and Contact


14/15 Belgrave Square

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Early bird fees before Friday 3 May 2019

£150   SCI Member
£55   SCI Student Member
£95   SCI Subsidised Member
£195   Non-Member

Standard fees after Friday 3 May 2019

£200   SCI Member
£85   SCI Student Member
£145   SCI Subsidised Member
£245   Non-Member

Become SCI Member and save on this and future events

See Membership Options

You must sign up for membership to join this event. FREE membership options available.

Booking Process/Deadlines

For booking terms and conditions click here.

CPD Info

SCI Members attending this meeting are able to claim CPD points.

 CPR Accredition Logo

Call for Abstracts

An abstract of maximum one A4 page or 300 words, indicating title, authors and preference for presentation option (15 or 30 minute oral, or poster) should be sent to conferences@soci.org by Friday 15 March 2019 with the subject line "TUPP 2019 – abstract submission". Subjects for presentation can include results, reviews or plans and may have already been presented elsewhere. Naturally, there are limited oral presentation slots and these will be allocated to achieve a balanced programme.

Exhibition & Sponsorship

An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email conferences@soci.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.

Organising Committee
  • Nicola Chessum, SCI / The Institute of Cancer Research
  • David Leese, SCI / Concept Life Sciences Ltd
  • Jayshree Mistry, SCI / Modgraph Consultants
  • Manisha Naik, SCI / Lilly
  • Jamie Scott, SCI / AstraZeneca

Become an SCI Member to receive events discounts

Join SCI